Accessibility Menu
Entera Bio logo

Entera Bio(NASDAQ) ENTX

Current Price$2.00
Market Cap$98.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-68%
5 Year-64%
1 Year-3%
1 Month+64%
Entera Bio last closing stock price
MetricPriceDate
Last closeUSD 1.992026-07-20
Entera Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+21.34%USD 1.642026-07-13
1 month+64.46%USD 1.212026-06-18
3 month+67.23%USD 1.192026-04-21
Year to date+2.58%USD 1.942025-12-31
1 year-2.93%USD 2.052025-07-18
3 year+136.9%USD 0.842023-07-21
5 year-63.75%USD 5.492021-07-21
Since inception-68.31%USD 6.282018-06-28

Entera Bio Financials at a Glance

Market Cap

$98.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.38M

EPS (TTM)

-$0.26

P/E Ratio

-7.56

Dividend

$0.00

Beta (Volatility)

0.51 (Low)

Price

$2.00

Volume

42,759.704

Open

$1.99

Previous Close

$1.99

Daily Range

$1.91 - $2.02

52-Week Range

$0.91 - $3.22

Estimated Earnings Date

Aug 14, 2026

ENTX News

Foolcom-Featured.png

Entera Bio Beats Q2 EPS Estimates

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Entera Bio

Entera Bio develops oral medicines for people with chronic hormone and bone disorders. Its tablets aim to replace daily injections, making treatment easier for patients. The company’s work targets conditions like osteoporosis and low parathyroid hormone levels.

Pills, Not Needles: What Entera Bio Sells

  • EB613 (Osteoporosis tablet): Oral treatment for bone loss in older adults; no product revenue yet.
  • EB612 (Hypoparathyroidism tablet): Oral therapy for people with low parathyroid hormone; no product revenue yet.
  • Oral GLP-1/Glucagon Program: Experimental pill for obesity and metabolic diseases, developed with OPKO Health.
  • Oral GLP-2 Program: Early-stage pill for short bowel syndrome, also with OPKO Health.
  • Research Services: Contract research for partners; all recognized revenue in 2024 and the first half of 2025 was from research services.

Growth Spurts and Strategic Moves

  • Signed a research and license deal with OPKO Health in March 2025 for new oral therapies.
  • Expanded its at-the-market (ATM) equity program in January 2025 to raise more capital.
  • Advanced EB613 to Phase 3 trial planning after U.S. FDA feedback in 2025.
  • Issued 3,685,226 shares to OPKO Health for $8 million in 2025, funding joint projects.

Why Entera Bio Stands Out (Without Standing on a Soapbox)

Entera Bio focuses on turning injectable protein drugs into oral tablets, aiming to improve patient comfort and adherence. Its proprietary N-Tab technology helps protect fragile medicines in the stomach, making oral delivery possible. The company’s small size allows for focused research and quick adaptation to new opportunities.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, down 100% from Q2 2024.
  • Operating loss was $2.7 million in Q2 2025, up 23% year-on-year.
  • Cash and equivalents and restricted cash totaled $18.9 million as of June 30, 2025.
  • All revenue in 2024 and 2025 came from research services, not product sales.
  • R&D expenses rose 40% to $1.5 million in Q2 2025.

Bottom Line

Entera Bio is working to make complex protein drugs easier to take by mouth. The company remains in the research stage, with no product sales and ongoing need for funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

22

CEO

Miranda J. Toledano, MBA

Website

www.enterabio.com

Headquarters

Jerusalem, JM 9112002, IL

ENTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-87.97%

Return on Capital

-84.83%

Return on Assets

-94.27%

Earnings Yield

-13.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$98.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

49.29M

Volume

42.76K

Avg. Volume

1.02M

Financials (TTM)

Gross Profit

-$15.00K

Operating Income

-$12.51M

EBITDA

-$12.35M

Operating Cash Flow

-$9.49M

Capital Expenditure

-$105.31K

Free Cash Flow

-$9.59M

Cash & ST Invst.

$4.14M

Total Debt

$448.00K

Entera Bio Performance Analysis

Entera Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 134,000-76.5%
20232023-12-31USD 0N/A
20242024-12-31USD 181,000N/A
20252025-12-31USD 42,000-76.8%
Entera Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Entera Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.45-2.7%
20232023-12-31USD -0.31-32.5%
20242024-12-31USD -0.25-17.3%
20252025-12-31USD -0.25-2.3%
Entera Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.2%
Q32025-09-30-19.9%
Q42025-12-314.0%
Q12026-03-31-12.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$7.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$98.09MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.46M

N/A

Employees

22

N/A

Net Income

-$3.51M

-36.5%

EBITDA

-$3.50M

-36.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.14M

-67.1%

Total Debt

$448.00K

+103.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$263.00K

+415.7%

Short Term Debt

$185.00K

+9.5%

Return on Assets

-94.27%

N/A

Return on Invested Capital

-1.08%

N/A

Free Cash Flow

-$3.09M

-118.8%

Operating Cash Flow

-$3.09M

-120.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SEERSeer, Inc.
$2.06+0.98%
SPROSpero Therapeutics, Inc.
$1.39-3.82%
ANIXAnixa Biosciences, Inc.
$3.66+5.72%
ABOSAcumen Pharmaceuticals, Inc.
$2.21-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$21.99+0.00%
MARAMara Holdings
$12.59+0.08%
UTZUtz Brands
$14.10+0.89%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.43+0.25%

Questions About ENTX

What is the current price of Entera Bio?

Entera Bio is trading at $1.99 per share.

What is the 52-week range for Entera Bio?

Over the past 52 weeks, Entera Bio has traded between $0.91 and $3.22.

How much debt does Entera Bio have?

As of the most recent reporting period, Entera Bio reported total debt of $448.00K.

How much cash does Entera Bio have on hand?

Entera Bio reported $11.93M in cash and cash equivalents in its most recent financial results.

What is Entera Bio’s dividend yield?

Entera Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services